Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study

Isabel Ferreira, University College London
Sara Croca, University College London
Maria Gabriella Raimondo, University College London
Manjit Matharu, Institute of Neurology and The National Hospital for Neurology and Neurosurgery
Sarah Miller, Institute of Neurology and The National Hospital for Neurology and Neurosurgery
Ian Giles, University College London
David Isenberg, University College London
Yiannis Ioannou, University College London
John G. Hanly, Dalhousie University
Murray B. Urowitz, University of Toronto

Only first 10 authors above; see publication for full author list.

Journal Title: Arthritis Research and Therapy
Volume: Volume 19, Number 1
Publisher: BioMed Central | 2017-12-22, Pages 287-287
Type of Work: Article | Final Publisher PDF
Publisher DOI: 10.1186/s13075-017-1495-6
Permanent URL: https://pid.emory.edu/ark:/25593/s72c0

Final published version: http://dx.doi.org/10.1186/s13075-017-1495-6

Copyright information:
© 2017 The Author(s).
This is an Open Access work distributed under the terms of the Creative Commons Attribution 4.0 International License (https://creativecommons.org/licenses/by/4.0/).
Nitrated nucleosome levels and neuropsychiatric events in systemic lupus erythematosus; a multi-center retrospective case-control study

Isabel Ferreira 1, Sara Croca 1, Maria Gabriella Raimondo 1, Manjit Matharu 2, Sarah Miller 2, Ian Giles 1, David Isenberg 1, 3, Yiannis Ioannou 1, 3, John G. Hanly 4, Murray B. Urowitz 5, Nicole Anderson 6, Cynthia Aranow 6, Anca Askanase 7, Sang-Cheol Bae 8, Sasha Bernatsky 9, Ian N. Bruce 10, Jill Buyon 11, Ann E. Clarke 12, Mary Anne Dooley 13, Paul Fortin 14, Ellen Ginzler 15, Dafna Gladman 5, Caroline Gordon 16, Murat Inanc 17, Søren Jacobsen 18, Kenneth Kalunian 19, Diane Kamen 20, Munther Khamashta 21, Sam Lim 22, Susan Manzi 23, Joan Merrill 24, Ola Nived 25, Christine Peschken 26, Michelle Petri 27, Rosalind Ramsey-Goldman 28, Guillermo Ruiz-Irastorza 29, Jorge Sanchez-Guerrero 30, Kristjan Steinson 31, Gunnar K. Sturfelt 25, Ronald van Vollenhoven 32, Daniel J. Wallace 33, Asad Zoma 34 and Anisur Rahman 1

Abstract

Background: In patients with systemic lupus erythematosus (SLE) there is no serological test that will reliably distinguish neuropsychiatric (NP) events due to active SLE from those due to other causes. Previously we showed that serum levels of nitrated nucleosomes (NN) were elevated in a small number of patients with NPSLE. Here we measured serum NN in samples from a larger population of patients with SLE and NP events to see whether elevated serum NN could be a marker for NPSLE.

Methods: We obtained serum samples from patients in the Systemic Lupus International Collaborative Clinics (SLICC) inception cohort. This included 216 patients with NP events and two matched controls with SLE but no NP events for each of these patients. For the NP patients we tested samples taken before, during and after the NP event.

Results: Twenty-six patients had events attributed to SLE according to the most stringent SLICC attribution rule. In these patients there was no association between onset of event and elevated serum NN. In 190 patients in whom events were not attributed to SLE by the SLICC rules, median serum NN was elevated at the onset of event ($P = 0.006$). The predominant clinical features in this group of 190 patients were headache, mood disorders and anxiety.

Conclusions: Serum NN levels rise at the time of an NP event in a proportion of patients with SLE. Further studies are needed to determine the value of serum NN as a biomarker for NPSLE.

Keywords: Systemic lupus erythematosus, Neuropsychiatric, Nucleosomes, Nitration
Background
Neuropsychiatric manifestations of systemic lupus erythematosus (NPSLE) can take many different forms as defined by the American College of Rheumatology (ACR) case definitions in 1999 [1]. A study from the Systemic Lupus International Collaborative Clinics (SLICC) inception cohort in 2011 showed that 40% of 1206 newly diagnosed patients with SLE followed for a mean of 1.9 years developed at least one NP event [2]. Those with NP events had reduced quality of life, but the majority of these events were not attributed to SLE.

The NP events in the SLICC study were defined as either attributable to SLE or not attributable to SLE according to pre-determined classification rules [2]. For example, all isolated headaches (not occurring in association with another NPSLE event) were classified as not being attributable to SLE. Only a minority (30%) of the 843 NP events analysed were attributed to SLE, but these events were more likely to resolve than those not due to SLE [2]. This observation underlines the importance of developing biomarkers to identify those NP events that are caused by SLE. Currently there are no serological or imaging markers that will do this accurately, though an association between antiphospholipid antibodies and cerebrovascular events has been reported [3]. Potential biomarkers for NPSLE that have previously been studied are autoantibodies, cytokines or chemokines (reviewed in [4]). Despite a large number of studies over the last 30 years none of these biomarkers has shown a robust association with either NPSLE in general or with any specific NPSLE manifestation [4]. Similarly, a multi-centre report of neuroimaging appearances in 112 patients with NPSLE [5] identified no specific findings on magnetic resonance imaging (MRI) that clearly characterised NPSLE. The most common appearance was of non-specific vascular abnormalities.

In a recent paper we used a novel capture enzyme-linked immunosorbent assay (ELISA) to measure levels of nitrated nucleosomes (NN) in patients with SLE. Nucleosomes are released from apoptotic cells and the removal of this apoptotic debris is retarded in patients with SLE [6]. Both nucleosome level and anti-nucleosome antibodies are elevated in patients with SLE [7] and the latter are associated with disease activity, especially lupus nephritis [8]. Williams et al. used a monoclonal murine anti-nucleosome antibody 4H7 to assay serum nucleosome levels in 140 patients with SLE. They showed that nucleosome levels are strongly associated with disease activity measured by the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI) score and were particularly high in patients with active nephritis or NPSLE [9]. Deposits of extracellular chromatins are found in renal biopsies from patients with lupus nephritis [10].

Nitric oxide (NO) produced by the endothelium [11] can cause irreversible nitration of tyrosine residues within proteins. Levels of serum NO are elevated in patients with SLE [11] and nitrotyrosine levels are higher in patients with active lupus nephritis than in those without nephritis [12].

Thus, since both nitration and nucleosome levels are associated with active SLE, our hypothesis was that levels of NN could be a marker of disease activity in patients with SLE. We measured serum NN in 397 samples taken longitudinally from 49 patients (mean 8 samples per patient) with SLE at times of different disease activity [13]. Serum NN levels were significantly higher in patients with SLE than in healthy control subjects or patients with other autoimmune rheumatic diseases [13]. However, only a subgroup (n = 31) of the patients with SLE had detectable serum NN at any time point. In those 31 patients, serum NN did vary over time but not in parallel with disease activity. Patients with NPSLE flares (defined as scoring A or B in the neuropsychiatric domain of the British Isles Lupus Assessment Group (BILAG) index) had mean NN twice the level in those without NP flares. However, this difference was based on only 18 samples from 11 patients and was not statistically significant [13].

To extend this research, we obtained serum samples from patients in the large SLICC inception cohort with documented NP events, and control samples from patients in the cohort without NP events. We tested serum NN in all patients, including longitudinal samples taken before, during and after the NP event. The objective was to determine if a transient rise in serum NN occurred concurrently with an NP event.

Methods
All samples were obtained from patients enrolled in the SLICC inception cohort. This cohort has been described in previous papers [2, 3, 14]. Briefly, it comprises over 1600 patients recruited within 15 months of being diagnosed with SLE, from 31 centres across North America, Europe and Asia. All patients gave informed consent and ethical approval for the study was obtained by the institutional research ethics review board at each participating centre. Clinical data and blood samples from these patients were collected annually and submitted to the study centres in Toronto and Halifax, Canada.

Neuropsychiatric (NP) events
An enrolment window extended from 6 months prior to the diagnosis of SLE up to the actual enrolment date. NP events were characterized within this window using the ACR case definitions for 19 NP syndromes [1]. These events were diagnosed by clinical evaluation supported by investigations, if clinically warranted, as per the ACR guidelines. Patients were reviewed annually within a 6-month window around the anniversary of
new NP events (since the last study visit) and the status of previous NP events since the last study visit were determined at each assessment.

Attribution of NP events

In keeping with other publications on NP events within the SLICC NPSLE inception cohort, the same decision rules were used to determine the attribution of all NP events [2, 15]. To optimize consistency this determination was performed at the central coordinating centre in Halifax using data provided in the case record form by individual SLICC sites. Factors considered in the decision rules included: (i) the time of onset of NP event(s) in relation to the diagnosis of SLE; (ii) concurrent non-SLE factor(s), identified from the ACR glossary, which accompanied the case definitions of NP events [1] as potential causes (“exclusions”) or contributing factors (“associations”) for each NP syndrome and (iii) “common” NP events that are frequent in normal population controls as described by Ainiala et al. [16]. These included all isolated headaches, mild depression (mood disorders failing to meet criteria for “major depressive-like episodes”), anxiety, mild cognitive impairment (deficits in fewer than three of the eight specified cognitive domains) and polyneuropathy without electrophysiological confirmation. Two attribution decision rules of different stringency (models A and B) were developed as described in detail elsewhere [2, 15]. NP events that fulfilled criteria for model A (most stringent) or for model B (least stringent) were attributed to SLE. By definition, all NP events attributed to SLE using model A were included in the group of NP events using model B. Those events that did not fulfill these criteria were attributed to non-SLE causes (non-A, non-B events). Non-A, non-B events comprised 70% of all events [2].

We tested samples from 26 patients with model-A NP events and 190 with non-A, non-B events (i.e. 216 patients with NP events in total). For each of these patients we attempted to obtain and test three samples; one from the date closest to the event, one from before that date and one from after. These were defined as the onset, pre-event and post-event samples, respectively. For each of the 216 patients with NP events we tested samples from two age-matched and sex-matched controls from the inception cohort who had no recorded NP events. Only one sample from each control subject was tested. We also tested samples from 16 patients with a history of chronic migraine who did not have SLE or any other autoimmune rheumatic disease. These patients were recruited with informed consent from the Headache Clinic at the National Hospital for Neurology and Neurosurgery, Queen Square, London, UK. In our previous paper [13] we showed that none of 37 healthy controls had any detectable serum NN, so we did not repeat testing of healthy controls in this study.

Assay for measuring nitrated nucleosomes

The whole assay was done at room temperature (RT) except where specified and plates were washed three to four times with PBS-0.1% Tween (PBST) between steps: 96-well streptavidin plates were divided in half and the test side was coated with biotinylated polyclonal goat anti-nitrotyrosine antibody (Abcam 27646) diluted 1:1000 in PBS, and the control side coated with PBS (75 μL per well). After one hour incubation plates were washed and blocked with 200 μL of 0.5% ovalbumin in PBST (OVA-BST) for one hour. After washing, serum samples were loaded in duplicate onto the plates (100 μL/well) at 1:30 dilution in PBS, such that each sample was loaded in two wells on the test side and two matching wells on the control side. After one hour incubation at 37 °C and washing, 50 μL per well of rabbit anti-histone H3 antibody (sc-10809, Santa Cruz Biotechnology) diluted at 1:2000 in OVA-BST was added and the plates were incubated for one hour. After washing, 50 μL per well of goat anti-rabbit IgG horse radish peroxidase (HRP) conjugate (Dako P0448) diluted at 1:2000 in 0.5% OVA-BST was added. After incubating for one hour and washing, HRP substrate was added (100 μL per well) and incubated for 10 min. The reaction was stopped with 100 μL sulphuric acid and optical density (OD) read at 450 nm. The net optical density (OD) reading for each sample was calculated by subtracting the OD in the control well from that in the matching test well to exclude non-specific background binding.

In order to be able to compare OD values obtained from different plates on different days we prepared an in-house standard positive control sample that was loaded in serial dilutions (range 1:15−1:120) on every plate. This in-house standard was prepared by pooling serum samples from several patients who had been found to have high serum NN levels in this assay. The mean net OD from duplicate test samples was converted to absorbance units (AU) by comparison to the standard curve of OD for the serial dilutions of the positive control sample on each plate; 100 AU was defined as the OD given by a 1:30 dilution of the positive control sample. The OD for this sample was reproducibly high, ranging between 1.03 and 1.37. This assay was reproducible with an intra-plate and inter-plate coefficient of variation of < 10%.

Statistical analysis

All statistical analysis was done using Prism Graphpad 6.0® (GraphPad Software Inc, La Jolla, CA 92037 USA). The main outcome measure was serum NN, which did not follow a normal distribution (Shapiro-Wilk normality
test). The highly positive skewed distribution could not be transformed to a normally distributed scale, thus the outcomes were assumed to follow a negative binomial distribution and non-parametric tests were selected. Variables measured at the patient level were compared between groups using either Fisher’s exact test for the categorical variables or the unpaired t test for continuous variables. Continuous variables with a positively skewed distribution were log-transformed before the analysis.

Results

Table 1 shows the demographic and medication data for each of the subject groups. Table 2 shows the type of NP event in the model A and the non-A, non-B NP event groups. As would be expected from the SLICC attribution rules, the groups are very different. In the non-A, non-B group 185/190 events were headache, anxiety disorder or mood disorder, whereas these three manifestations accounted for only one case in the model-A group.

Considering all 216 patients who had events, the median time between the date of the NP event and the date of the onset sample was 2 months (maximum 6 months). Of the onset samples, 67 came from a time point before the event and 149 from after the event.

Patients with model-A NP events

Figure 1 shows that there were no significant differences between median serum NN in the pre-event, onset and post-event samples or matched controls ($P = 0.46$, one-way analysis of variance (ANOVA)).

Patients with non-A, non-B NP events

Figure 2 shows that median serum NN was highest in the onset sample compared to pre-event or post-event samples ($P = 0.006$, one-way ANOVA). Mean serum NN for onset samples was also significantly higher than in the matched controls ($P < 0.001$, Wilcoxon test).

Table 1 Demographic and treatment characteristics of patients with SLE studied at the time of the onset sample

|                  | Model-A NP event | Matched controls for model-A NP events | Non-A, non-B NP events | Matched controls for non-A, non-B NP events |
|------------------|------------------|---------------------------------------|------------------------|-------------------------------------------|
| Number of subjects | 26               | 52                                    | 190                    | 380                                       |
| Mean (SD) age     | 34.4 (7.5)       | 36.9 (10.9)                           | 33.3 (11.8)            | 35.3 (11.5)                              |
| Gender (female:male) | 21:5             | 42:10                                 | 177:13                 | 353:27                                    |
| Ethnicity         | 9 W, 6 A-C, 4 SA, 4 EA, 3 H | 22 W, 12 A-C, 4 SA, 7 EA, 6 H, 1 other | 84 W, 30 A-C, 4 SA, 41 EA, 18 H, 13 other | 161 W, 61 A-C, 13 SA, 81 EA, 36 H, 26 other, 2 unknown |
| Median dose of corticosteroids (mg) | 10               | 0.25                                  | 7.5                    | 5                                         |
| Number (%) taking anti-malarials | 16 (61)          | 22 (42)                               | 140 (74)               | 222 (58)                                  |
| Number (%) taking immunosuppressant drugs | 13 (50)          | 10 (19)                               | 71 (37)                | 144 (38)                                  |

Demographic and clinical characteristics of the patients with systemic lupus erythematosus (SLE) studied in all four groups. NP neuropsychiatric, W white, A-C Afro-Caribbean, EA East Asian, SA South Asian, H Hispanic.

Discussion

Apart from the recognised association between antiphospholipid antibodies and cerebrovascular disease [3], biomarkers previously thought to show great promise in the management of NPSLE, such as anti-ribosomal P antibodies [17] and anti N-methyl-D-aspartate receptor antibodies [18], have not come into widespread clinical
Table 2  Type of NP event in patients with model A compared to non-A, non-B events

| Type of NP event                             | Number of events in model-A group (total n = 26) | Number of events in non-A, non-B group (total n = 190) |
|----------------------------------------------|--------------------------------------------------|-------------------------------------------------------|
| Acute inflammatory demyelinating polyneuropathy | 1                                                | 0                                                    |
| Aseptic meningitis                           | 1                                                | 1                                                    |
| Cerebrovascular disease                      | 2                                                | 0                                                    |
| Headache                                     | 0                                                | 157                                                  |
| Mononeuropathy                               | 3                                                | 1                                                    |
| Cranial neuropathy                           | 4                                                | 0                                                    |
| Polyneuropathy                               | 1                                                | 0                                                    |
| Seizures                                     | 7                                                | 2                                                    |
| Acute confusional state                      | 1                                                | 1                                                    |
| Anxiety disorder                             | 0                                                | 10                                                   |
| Cognitive dysfunction                        | 1                                                | 0                                                    |
| Mood disorders                               | 1                                                | 18                                                   |
| Psychosis                                    | 4                                                | 0                                                    |

The table shows the nature of the neuropsychiatric (NP) events comparing patients in the model-A and non-A, non-B groups.

Fig. 1  Serum nitrated nucleosomes (NN) levels in pre-event, onset and post-model-A event samples compared to matched controls (MC). Pre-event samples were available for 12 patients, onset samples for 24 patients and post-event samples for 25 patients. AU absorbance units.
use. It is difficult to validate any putative biomarker in NPSLE because it is a rare condition and because many patients with SLE have NP events not caused by the disease itself [2]. Our previous study had raised the possibility that elevated serum NN could be a marker of NPSLE, but was limited by small numbers of patients and a limited variety of NP events. In order to address these limitations, we accessed samples and clinical data from the SLICC inception cohort, which is one of the largest populations in which comprehensive data on NPSLE events are available. Even in this multi-national cohort of over 1600 patients, we were only able to study 26 patients with model-A NP events and for half of these 26 patients we did not have a full set of pre-event, onset and post-event samples. We could not show any relationship between elevated serum NN and NP events in these 26 patients.

Our original purpose in including patients with NP events not attributed to SLE was as a control group in which we did not expect to see a rising and falling pattern of serum NN. However, in the event, the serum NN level was statistically higher at event onset in this group than in the pre-event or post-event samples or in the matched controls. We did not detect any similar statistically significant result in patients with model-A NP events, perhaps due to the much smaller numbers in that group.

We considered a number of possible explanations for these serum NN results in patients with non-A, non-B events. The highly significant \( P \) values suggest that this was not a random or chance finding. These were not simply individuals with constitutively high levels of serum nitration, as the pre-event samples had very low serum NN levels. Since the majority of the events were headaches it was possible that elevated serum NN is a non-specific effect of headache, but this seems unlikely because we found no NN in serum from any patients who suffer chronic headache but do not have lupus. It was also possible that the rise in serum NN could have been due to lupus activity in non-NP systems but we found no association between serum NN and any marker of global, serological or organ-specific disease activity that was assessed in this paper (in any of the patient groups). Nor did we find such associations in our previous paper [13].

Under conditions of systemic inflammation, excess nitric oxide (NO) produced by the vascular endothelium [11] can cause irreversible nitration of tyrosine residues on serum proteins including histones in nucleosomes. NO is also believed to contribute to the causation of headaches through its effects on cerebral and extracerebral cranial blood flow [19]. In patients with SLE, serum nitrite plus nitrate level (an index for NO production) correlates with disease activity and levels of anti-dsDNA antibodies [11, 12]. There are also potential links between nitration and NPSLE. Human astrocytes are known to express inducible nitric oxide synthase

![Fig. 2 Serum nitrated nucleosomes (NN) levels in pre-event, onset and post-non-A, non-B event samples compared to matched controls (MC). Pre-event samples were available for 106 patients, onset samples for 182 patients and post-event samples for 181 patients. AU absorbance units.](image-url)
(iNOS) which can be stimulated by cytokines including interleukin-1β and interferon gamma [20]. A Swedish group showed in 1998 that total cerebrospinal fluid (CSF) (nitrite + nitrate) was higher in patients with NPSLE than in age-matched and sex-matched controls and higher in patients with severe compared to those with mild NPSLE [21]. In a subsequent study of 30 patients who had NPSLE (with clinical features fulfilling the ACR case definitions [1]), the same group confirmed significantly higher CSF (nitrate + nitrite) in 7 patients with severe NPSLE (psychosis, dementia, combinations of several NP manifestations) compared to 23 patients with mild or moderate NPSLE (including cognitive impairment, seizures, headache, anxiety, mood disorders) [22].

The concept of lupus headache is complex and many papers have suggested that it is of limited usefulness because headache is such a common complaint (in people with or without SLE). For example, in a meta-analysis, Mitsikostas et al. showed that although headache occurs in 50% of patients with SLE, this is not significantly different from the population prevalence of this very common symptom [23]. Furthermore there was no clear evidence that headache in patients with SLE was related to disease activity or arose from a specific autoimmune or inflammatory mechanism [23]. Analysis of headaches in the SLICC inception cohort showed a prevalence of 17.8% at enrolment and that 58% of subjects suffered headache at some time over a 10-year follow-up period [14]. Only 27 of 697 headaches were identified as lupus headaches by the treating physician. However, there was no consensus on the characteristics of headache in this group as reflected by the headache subtypes in the case definitions. Of these 27 lupus headaches, 26 resolved over a mean follow-up period of 3.8 years [14].

There are a number of limitations affecting our analysis. As noted previously, we did not have a full complement of samples for most of the patients with model-A events. Since clinical data and blood samples are obtained annually for the SLICC study, the time period between the pre-event, onset and post-event samples ranged from a few months to several years. However, the onset samples were from time points close to the event (median gap 2 months, maximum 6 months). In our previous smaller study in 49 patients, higher serum NN was seen in patients on hydroxychloroquine or immunosuppressant drugs. In the current study, the patients with model-A NP events were on higher corticosteroid doses and were more likely to be taking immunosuppressant drugs than the matched controls (Table 1), but there were no corresponding
differences between the patients with non-A, non-B events and their controls. We considered obtaining further samples from patients who had NP events that were due to SLE under model B but not model A. However, the study centre in Toronto informed us that there were only eight such subjects for whom sufficient samples were available and this was not pursued.

Although we have used the term nitrated nucleosomes in this paper, we stressed in our previous paper and repeat here that our assay could potentially detect any analyte that contains both histones and nitrotyrosine, for example nucleosome fragments or nitrated free histones. However, published evidence shows that circulating free histones are rarely found except in conditions such as severe trauma [24]. Specifically, although the presence of circulating nucleosomes in blood has been established for many years [7, 25], sub-nucleosome components are rapidly cleared through the liver and thus are rarely detectable [26]. In fact circulating histones are toxic to endothelial cells [24]. It is important to be clear, however, that this assay has not been validated using purified nucleosomes and this validation would be an important step before it could be used in clinical practice.

Use of the serum NN assay clinically cannot yet be advocated based on these results alone. Though the capture ELISA is reproducible in our hands, with inter-plate and intra-plate variation < 10%, it has not yet been carried out elsewhere and the standard positive control used to quantify the results is a blend of serum from our patients.

Conclusions
In previous studies both nitration and nucleosomes have been found to be elevated in association with active SLE. In this multi-centre study we found that serum NN levels rise at the time of an NP event in a proportion of patients with SLE, including some cases of headache. Further studies are needed to determine the value of serum NN as a biomarker for NPSLE. The NN assay will require further validation and standardisation of the nature and biochemistry of the antigen being recognised.

Abbreviations
ACR: American College of Rheumatology; ANOVA: Analysis of variance; AU: Absorbance units; BILAG: British Isles Lupus Assessment Group; ELISA: Enzyme-linked immunosorbent assay; HRP: Horseradish peroxidase; INOS: Inducible nitric oxide synthase; NN: Nitrated nucleosomes; NO: Nitric oxide; NP: Neuropsychiatric; OD: Optical density; PBS: Phosphate-buffered saline; SLE: Systemic lupus erythematosus; SLEDAI: Systemic lupus erythematosus disease activity index; SLICC: Systemic Lupus International Collaborative Clinics

Acknowledgements
Not applicable.

Funding
This work was funded by LUPUS UK, The Rosetrees Trust and Arthritis Research UK Programme Grant 19423, and was supported by the National Institute for Health Research (NIHR) University College London Hospitals Biomedical Research Centre. Drs Ioannou and Isenberg are also supported by Arthritis Research UK Grant 20164. Dr. Hanly’s work was supported by the Canadian Institutes of Health Research (research grant MOP-86526). Dr. Sang-Chool Bae’s work was in part by unrestricted grant (Hanyang University 201600000001587). Dr. Caroline Gordon’s work was supported by Lupus UK, Sandwell and West Birmingham Hospitals National Health Service (NHS) Trust and the NIHR/Wellcome Trust Clinical Research Facility in Birmingham. Dr Petri and the Hopkins Lupus Cohort are supported by the National Institutes of Health (NIH) (grant AR43727). The Montreal General Hospital Lupus Clinic is partially supported by the Singer Family Fund for Lupus Research. Dr. Clarke holds The Arthritis Society Chair in Rheumatic Diseases at the University of Calgary. Dr. Paul R. Fortin presently holds a tier 1 Canada Research Chair on Systemic Autoimmune Rheumatic Diseases at Université Laval, and part of this work was done while he was still holding a Distinguished Senior Investigator of The Arthritis Society. Dr. Bruce is an NIHR Senior Investigator and is funded by Arthritis Research UK, the National Institute for Health Research Manchester Biomedical Research Unit and the NIHR/Wellcome Trust Manchester Clinical Research Facility. The authors declare that they have no competing interests.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Centre for Rheumatology Research, University College London, Fourth Floor Rayne Institute, 5 University Street, London WC1E 6JF, UK. 2Headache Group, Institute of Neurology and The National Hospital for Neurology and Neurosurgery, Queen Square, London, UK. 3Arthritis Research UK Centre for Neurology, Queen Square, London, UK.
Adolescent Rheumatology, UCL/UCLH/Great Ormond Street Hospital, London, UK. 9Department of Rheumatology, Dallhouse University and Queen Elizabeth II Health Sciences Center, Halifax, NS, Canada. 10Lupus Program, Centre for Prospective Studies in The Rheumatic Disease and Krembil Research Institute, Toronto Western Hospital, University of Toronto, Toronto, ON, Canada. 11Department of Medicine, University of California, San Francisco, CA, USA. 12Department of Rheumatology, Brigham and Women's Hospital, Boston, MA, USA. 13Thurston Arthritis Research Center, University of North Carolina, Chapel Hill, NC, USA. 14Department of Rheumatology, Medical University of South Carolina, Charleston, SC, USA. 15FRPC Division of Women's Health, King's College, London, UK. 16Department of Medicine, Emory University, Atlanta, GA, USA. 17Allegheny Health Network, Pittsburgh, PA, USA. 18Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA. 19Department of Rheumatology, Lund University, Lund, Sweden. 20Division of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada. 21Johns Hopkins University School of Medicine, Baltimore, MD, USA. 22Northwestern University, Feinberg School of Medicine, Chicago, IL, USA. 23Autoimmune Diseases Research Unit, Department of Internal Medicine, BioCruces Health Research Institute, Hospital Universitario Cruces, University of the Basque Country, Barakaldo, Bizkaia, Spain. 24Mount Sinai Hospital and University Health Network, Toronto, ON, Canada. 25Department of Rheumatology, Landspítali University Hospital, Reykjavík, Iceland. 26Department of Rheumatology, Karolinska University Hospital, Solna, Sweden. 27Department of Rheumatology, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada. 28Department of Medicine, University of California, Los Angeles, CA, USA. 29Autoimmune Diseases Research Unit, The Université Laval (CHUL), Québec, QC, Canada. 30Mount Sinai Hospital and University Health Network, Toronto, ON, Canada. 31Department of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. 32Rheumatology Unit, University Health Centre, Montreal, QC, Canada. 33Department of Rheumatology, McGill University Health Centre, Montreal, QC, Canada. 34Department of Rheumatology, Guy’s & St Thomas’ Hospital, London, UK. 35Department of Medicine, Rady Faculty of Health Sciences, University of Manitoba, Winnipeg, MB, Canada. 36Johns Hopkins University School of Medicine, Baltimore, MD, USA. 37Northwestern University, Feinberg School of Medicine, Chicago, IL, USA. 38Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, USA. 39Department of Rheumatology, Medical University of South Carolina, Charleston, SC, USA. 40Department of Medicine, University of North Carolina, Chapel Hill, NC, USA. 41Department of Rheumatology, Columbia University, New York, NY, USA. 42Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea. 43Division of Clinical Epidemiology and Rheumatology, McGill University Health Centre, Montreal, QC, Canada. 44Division of Rheumatology, Columbia University, New York, NY, USA. 45Department of Rheumatology, Columbia University, New York, NY, USA. 46Department of Rheumatology, University of Toronto, Toronto, ON, Canada. 47Department of Rheumatology, University Health Centre, Montreal, QC, Canada. 48Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, The University of Manchester, and NIHR Manchester Musculoskeletal Biomedical Research Unit, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK. 49New York School of Medicine, New York, NY, USA. 50Division of Rheumatology, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada. 51Department of Rheumatology, Columbia University, New York, NY, USA. 52Department of Rheumatology, Columbia University, New York, NY, USA. 53Department of Rheumatology, Columbia University, New York, NY, USA. 54Department of Rheumatology, Columbia University, New York, NY, USA. 55Department of Rheumatology, Columbia University, New York, NY, USA. 56Department of Rheumatology, Columbia University, New York, NY, USA. 57Department of Rheumatology, Columbia University, New York, NY, USA. 58Department of Rheumatology, Columbia University, New York, NY, USA. 59Department of Rheumatology, Columbia University, New York, NY, USA. 60Department of Rheumatology, Columbia University, New York, NY, USA.